SeekingAlpha•2026-04-20
Immunovant: Best-In-Class Ambitions, Still UnprovenIMVT — Immunovant Inc
NASDAQ · Biotechnology · Biotechnology
$28.58+7.40%Market cap4.99B
- Latest Close
- $28.58
- 30-Day Move
- +7.4%
- Market Cap
- $5.0B
- Shares Outstanding
- 203,530,000
- P/B Ratio
- 4.11
- ROE
- -58.5%
Analyst consensus: Buy · 24 analysts
NASDAQ:IMVTBiotechnology / BiotechnologyDelayed public snapshot
Immunovant Inc
A read-only Alphactor snapshot forImmunovant Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$28.58
30-Day Move
+7.4%
Market Cap
$5.0B
Shares Outstanding
203,530,000
P/B Ratio
4.11
ROE
-58.5%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$28.58
+7.4%last 90 delayed daily bars
Market cap$5.0B
90D High
$30.09
90D Low
$22.79
Avg Volume
1,451,767
What stands out
IMVT is up 7.4% over the last 30 trading days shown on this page.
Latest operating income is $-114M, which helps anchor the headline ratios with an actual earnings figure.
Fundamentals snapshot
Latest Close
$28.58
30-Day Move
+7.4%
Market Cap
$5.0B
Shares Outstanding
203,530,000
P/B Ratio
4.11
ROE
-58.5%
ROA
-53.3%
Debt / Equity
0
Current Ratio
11.16
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-114M
Net Income
$-111M
Gross Margin
--
Net Margin
--
Current Ratio
11.16
Debt / Equity
0.00
Quality snapshot
Altman Z
40.49
Safe
Piotroski
2
Weak (0-3)
Cash Conversion
0.91x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-156M | $-157M | $-106M |
| 2023-12-31 | $0 | $-208M | $-211M | $-188M |
| 2024-12-31 | $0 | $-270M | $-259M | $-215M |
| 2025-12-31 | $0 | $-438M | $-414M | $-377M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$350M
Sell Value
$4M
Buys
1
Sells
31
Buy Value
$350M
Sell Value
$4M
Buy/Sell Ratio
0.03x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-23 | Stout Jay S | Sell | 2,754 | $29.62 |
| 2026-04-23 | Girao Tiago | Sell | 25,760 | $29.62 |
| 2026-04-08 | Gloria Melanie | Sell | 8,722 | $24.83 |
| 2026-04-08 | Van Tuyl Christopher | Sell | 5,165 | $24.83 |
| 2026-04-08 | Stout Jay S | Sell | 1,518 | $24.83 |
| 2026-04-08 | Stout Jay S | Sell | 8,614 | $24.83 |
| 2026-04-07 | Susman Robert Graham | A | 7,061 | $0.00 |
| 2026-04-07 | Susman Robert Graham | A | 13,880 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5,032,131 | 0.02% | 2026-02-28 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2,685,760 | 0.01% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2,558,295 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1,837,664 | 0.01% | 2025-12-31 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1,738,969 | 0.01% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 1,702,395 | 0.01% | 2026-02-28 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1,401,818 | 0.01% | 2026-02-28 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1,201,459 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
D.E. Shaw
Filed 2026-02-17
--
--
Two Sigma Advisers
Filed 2025-05-15
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
$432M
+15.4%
Vanguard Group
Filed 2026-01-29
$198M
+14.0%
BlackRock
Filed 2024-05-10
$145M
--
Geode Capital Management
Filed 2026-02-09
$47M
+3.1%
Goldman Sachs
Filed 2026-02-10
$33M
-12.6%
Analyst consensus?
Rating(?)
4.13
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
24
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.